FDA approves Ebanga for the treatment of Ebola
TM for the treatment of Ebola.
Image/Dr. Frederick Murphy,CDC
Ebanga is now approved for treatment of infection caused by
Zaire ebolavirus in adult and pediatric patients (including neonates born to a mother who is RT-PCR positive for
Zaire ebolavirus infection).
Ebanga is the only FDA approved, single injection Ebola treatment which is available in a lyophilized form.
Ebanga (ansuvimab-zykl, formerly referred to as mAb114) is a monoclonal antibody isolated from a human survivor of the 1995 Ebola outbreak in Kikwit, a city in the DRC.
Wendy Holman, CEO and co-founder of Ridgeback, said: “I speak on behalf of the entire Ridgeback Bio team when I say thank you to all of the dedicated and thoughtful groups who helped contribute to this historic and important product approval. Ridgeback is grateful to NIAID’s Vaccine Research Center (VRC) and the Democratic Republic of the Congo’s (DRC) Institut National